Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESCAMS: Mesenchymal Stem Cells for MS
NCT02239393Phase 2Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jun 2015
- Primary completion
- Dec 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cells in multiple sclerosis (MS) (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoints: Number, time-frame and severity of adverse events at 24 weeks and Reduction in total number of gadolinium-enhancing lesions (GEL) at 24 weeks. Started Jun 2015; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02239393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239393.